FORA Capital LLC Acquires Shares of 11,077 Guardant Health, Inc. $GH

Key Points

• FORA Capital LLC has made a new investment of approximately $472,000 by purchasing 11,077 shares of Guardant Health during the first quarter.
• Guardant Health received multiple upgrades from analysts, with a consensus target price of $57.50 and a majority of analysts rating the stock as a Buy.
• Insider trading activity revealed that Guardian Health's CEO sold 100,000 shares valued at over $5 million, reflecting a 4.83% decrease in ownership.

FORA Capital LLC acquired a new stake in Guardant Health, Inc. (NASDAQ:GH - Free Report) during the 1st quarter, according to its most recent disclosure with the SEC. The fund acquired 11,077 shares of the company's stock, valued at approximately $472,000.

Other institutional investors have also added to or reduced their stakes in the company. Janney Montgomery Scott LLC bought a new stake in Guardant Health in the 1st quarter valued at $232,000. Stifel Financial Corp lifted its position in Guardant Health by 25.1% in the 4th quarter. Stifel Financial Corp now owns 49,927 shares of the company's stock valued at $1,525,000 after acquiring an additional 10,006 shares in the last quarter. Teacher Retirement System of Texas bought a new stake in Guardant Health in the 1st quarter valued at $866,000. Fifth Third Bancorp bought a new stake in Guardant Health in the 1st quarter valued at $279,000. Finally, Raymond James Financial Inc. bought a new stake in Guardant Health in the 4th quarter valued at $2,211,000. 92.60% of the stock is owned by institutional investors.

Guardant Health Stock Performance

GH traded up $2.95 on Monday, reaching $67.42. The company had a trading volume of 2,864,324 shares, compared to its average volume of 2,800,602. Guardant Health, Inc. has a fifty-two week low of $20.14 and a fifty-two week high of $67.51. The stock has a market cap of $8.41 billion, a P/E ratio of -20.13 and a beta of 1.45. The company's fifty day moving average is $51.69 and its 200 day moving average is $46.63.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.08. The company had revenue of $232.09 million during the quarter, compared to analyst estimates of $211.19 million. During the same quarter last year, the company posted ($0.84) EPS. The firm's quarterly revenue was up 31.0% on a year-over-year basis. Guardant Health has set its FY 2025 guidance at EPS. On average, sell-side analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Evercore ISI raised shares of Guardant Health to a "strong-buy" rating in a research report on Monday, July 14th. Scotiabank boosted their price objective on shares of Guardant Health from $57.00 to $60.00 and gave the company a "sector outperform" rating in a research report on Thursday, July 31st. Raymond James Financial boosted their price target on shares of Guardant Health from $59.00 to $61.00 and gave the stock an "outperform" rating in a research report on Thursday, July 31st. Mizuho boosted their price target on shares of Guardant Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a research report on Friday, June 13th. Finally, Piper Sandler reissued an "overweight" rating and set a $60.00 price target (up from $50.00) on shares of Guardant Health in a research report on Tuesday, May 6th. One analyst has rated the stock with a Strong Buy rating and sixteen have issued a Buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $57.50.

Insider Transactions at Guardant Health

In other Guardant Health news, Director Musa Tariq sold 3,213 shares of the business's stock in a transaction dated Wednesday, June 18th. The shares were sold at an average price of $49.47, for a total value of $158,947.11. Following the completion of the sale, the director owned 7,190 shares of the company's stock, valued at $355,689.30. The trade was a 30.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Meghan V. Joyce sold 3,337 shares of the business's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $47.22, for a total transaction of $157,573.14. Following the completion of the sale, the director directly owned 11,150 shares of the company's stock, valued at $526,503. This represents a 23.03% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 235,442 shares of company stock worth $11,848,325. Company insiders own 6.10% of the company's stock.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.